Advancements in the Treatment of Mesothelioma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 219
Special Issue Editor
2. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito 2, 67100 L’Aquila, Italy
Interests: malignant pleural mesothelioma; MPM; therapeutic targets; immunotherapy; chemotherapy; translational oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mesothelioma is a rare and fatal tumor. It originates on the mesothelial surfaces of the peritoneum, pleura, and other sites. Over the past twenty years, the combination of pemetrexed with cisplatin has been the only clinically approved first-line chemotherapy. Later, immunotherapy was proposed for the treatment of mesothelioma. Nevertheless, the prognosis remains poor, with an average survival of only 18 months. Therefore, it is urgent to identify novel targets for future therapies in the hope of improving patients’ survival and their quality of life.
The aim of this Special Issue of Biomedicines is to highlight the most recent progress in mesothelioma treatment. We encourage contributions on the topics of current diagnostic approaches, accepted therapies, experimental studies, future innovations, and potential therapies in the future.
Dr. Luciano Mutti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mesothelioma
- targeted therapy
- diagnostics
- checkpoint inhibitors
- immunotherapy
- chemotherapy
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
